The COG’s phase III AAML1831 clinical trial includes children with newly diagnosed FLT3-mutated AML (including both FLT3-ITD with an AR of >0.1 and FLT3-TKD) (NCT04293562) [60]. The gene discussed is FLT3; the disease is acute myeloid leukemia.